Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -0.53% | -0.54% | -2.24% | -0.57% |
| EV / EBITDA | 11,730.29 | -145.56 | -31.27 | 14.41 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | -11.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 90.19% |
| Cash Conversion Ratio | 0.89 | 0.86 | 0.88 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 1.84% | 5.25% | -293.02% | -56.42% |
| Safety | ||||
| Net Debt / EBITDA | -341.39 | 5.06 | 5.63 | -3.05 |
| Interest Coverage | -7,750.50 | 0.00 | 0.00 | 41.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -3,710.00 |